KRAS and neoplasm: We also looked at the sensitivity of tumor cells with WT KRAS to treatment with Indisulam, and demonstrated that KRAS4A was downregulated in response to both Indisulam and knockdown of RBM39 in H1650 cells (Supplementary Fig. 7F).